Since the time of its founding, Sysmex has grown by anticipating future needs, expanding its business model in the field of in-vitro diagnostics, and developing its business globally. Going forward, we will work to accelerate sustainable growth by quickly ascertaining changes in the operating environment and developing our business. Our business centers on in-vitro diagnostics (IVD), based on our mission of “Shaping the Advancement of Healthcare.” This mission is expressed in the “Sysmex Way,” the corporate philosophy of the Sysmex Group. By leveraging our unique management resources, we provide high-value-added products and services, aiming to contribute to a fulfilling and healthy society. In Sysmex’s main businesses of hematology, urinalysis, and immunochemistry, fundamental testing is conducted to check a patient’s physical condition and performed during medical checkups for disease prevention and early-stage detection. To this end, they are used for a wide range of other purposes, such as in treating a disease or managing its prognosis. On the other hand, in such fields as hemostasis and gene testing, tests are performed to measure a person’s physical condition in greater detail and are mainly used in the process of diagnosing and treating illnesses. Going forward, we plan to expand our lineup by developing proprietary reagent parameters and obtaining regulatory approval as we work to expand sales further. In addition, we aim to augment our presence in the IVD domain by launching new products in the FCM, life science, and other new business areas. In recent years, technological innovation and its application to the field of healthcare have been leading to the practical realization of new treatment methods. For example, cancer genomic medicine—a type of personalized medicine that enables treatment tailored to an individual patient’s constitution and disease—is coming to the fore. Realizing this type of medicine will require analysis based on the genetic testing of cancer cells. Sysmex is working to achieve this type of cancer genomic medicine and to make liquid biopsy a reality. A liquid biopsy involves testing a patient’s blood and body fluids, which places less of a burden on the patient than a physical biopsy. As a result, we aim to help improve patients’ quality of life and hold down healthcare expenses Sysmex provides products and services to customers around the world. In the IVD field, we are ranked seventh globally. Most companies in this sector are based in Europe and the United States; Sysmex is the only top-10 company headquartered in Asia. Notably, we have a leading share of the global market in the hematology field, with a share of more than 50%. Furthermore, in the hemostasis and urinalysis fields, we are using alliances to expand our portfolio and achieve a high share of the global market. Meanwhile, we are building a robust installed instrument base in the immunochemistry field, where we are developing our business, mainly in Asia. www.sysmex.co.kr email@example.com
The XN-9100 is a scalable, modular automation system, meeting the needs of labs across any size, complexity, and specialty. Decreased turnaround time and optimized labor utilization while maintaining high-quality patient results may be achieved through automatic workload balancing, hands-free rerun/reflex testing, and fully automated reflexive slide preparation. 1. Flexibility The XN-9100 is a fully automated hematology analyzing system that combines up to nine modules and is the only system that can connect with Hematology analyzer and Slidemaker to a Digital image analyzer for meeting all needs in the laboratory. The XN-9100 is optimized for Rerun/Reflex rules to fully automate slide reviews that have relied on manual work by automatically performing peripheral blood slide making and image analysis for abnormal samples during analysis. 2. HbA1c connectivity The XN-9100 can make the HbA1c as well as the CBC test fully automated through a single EDTA tube by connecting to Tosoh's HbA1c analyzer, HLC-723 G11. This dramatically improves sample loading, which relies on manual methods, to optimize workflow in the laboratory enabling pre- and post-analysis as needed. 3. Sorting/Archiving system TS-10 is a system that automatically sorts and archives samples according to the needs of the laboratory. It also enables a variety of connection patterns to reduce the risk of mistakes or infections by reducing unnecessary manual works and to maximize work efficiency by connecting to the XN-9100 to build an optimized automated system. 4. Integrated hematology middleware SWAM is a middleware optimized for laboratory data management, enabling integrated data management such as patients and QC, and digital image viewer to confirm patient-specific blood analysis results as well as scattergrams, flag messages, and cell images on a single screen. In addition, SWAM can dramatically improve the quality of work in the laboratory by automating various paperwork required for the Clinical Laboratory Accreditation Program.
CN Track system is “Hemostasis Automation system” designed to improve workflow in your lab. 1. Smart & Compact Automation system CN Track System which connects the transportation system and the CN series (CN-6000/CN-3000/CN-6500) and automates the overall process of hemostasis tests such as analytic and post-analytic. This system contributes to operating the laboratory efficiently. 2. Flexibility & Expandability CN Track System provides customized solutions depending on the laboratory environment, you can expand CN solution flexibly by connecting up to three analyzers to system handling up to 1,000 tests/hr. 3. Total parameters for Coagulation Disease CN Track System can combine CN-6000 and CN-6500 to measure not only routine coagulation parameters but also special Immuno coagulation parameters with the CLEIA method. It provides the overall hemostasis solution that can diagnose hemostasis diseases such as Thrombophilia, Hemophilia, Platelet disease, and anti-coagulant monitoring and contribute to diagnose and decide the treatment for patients. With decades of experience in hematology and urinalysis workflow automation and thousands of satisfied customers, you can experience in Sysmex automation solutions for the hemostasis work area.
The Immunochemistry system of Sysmex, HISCL-series, improve the value of diagnostic medicine by showing reliable result, high performance, and special markers. 1. High specificity by minimizing non-specific responses With Sysmex’s own Bind/Free Washing process, it minimizes non-specific responses and reduces the background of the result. The characteristics of these HISCL-series allow for high specificity implementation, which is a strong advantage for Hepatitis markers. 2. Analyzing time 17min/T for all samples By applying Sysmex’s technology to reaction temperature and antigen-antibody reactions in the instrument, all items can be reported results in 17 minutes and show throughput up to 200 Test/hour 3. Small sample volume 10~30㎕ for all parameters All tests can be tested with small sample volume(only 10-30㎕), reducing the burden of insufficient sample quantity during pediatric sample testing or re-test. The reason it can be tested with fewer samples is that higher sensitivity is implemented using the highly sensitive substrate SDP-Star®. 4. Special markers: M2BPGi, Presepsin, Respiratory marker The HISCL-Series has a variety of tests held only by Sysmex to diagnose and manage diseases early. Liver fibrosis blood marker M2BPGi which can screen and monitor liver disease, Presepsin for sepsis marker, and future respiratory markers KL-6 and SP-A are available on the HISCL-series. This improves the value of blood tests and contributes to the development of diagnostic medicine.